| Literature DB >> 35775605 |
Bidossessi Wilfried Hounkpe1, Carla Roberta Peachazepi Moraes1, Carolina Lanaro2, Magnun Nueldo Nunes Santos1, Fernando Ferreira Costa1,2, Erich Vinicius De Paula1,2.
Abstract
Hemolytic diseases such as Sickle Cell Disease (SCD) are characterized by a natural propensity for both arterial and venous thrombosis. The ability of heme to induce tissue factor (TF) activation has been shown both in animal models of SCD, and in human endothelial cells and monocytes. Moreover, it was recently demonstrated that heme can induce coagulation activation in the whole blood of healthy volunteers in a TF-dependent fashion. Herein, we aim to further explore the cellular mechanisms by which heme induces TF-coagulation activation, using human mononuclear cells, which have been shown to be relevant to in vivo hemostasis. TF mRNA expression was evaluated by qPCR and TF procoagulant activity was evaluated using a 2-stage assay based on the generation of activated factor X (FXa). Heme was capable of inducing both TF expression and activation in a TLR4-dependent pathway. This activity was further amplified after TNF-α-priming. Our results provide additional details on the mechanisms by which heme is involved in the pathogenesis of hypercoagulability in hemolytic diseases.Entities:
Keywords: Sickle cell anemia; heme; hemolysis; hypercoagulability; inflammation; tissue factor
Mesh:
Substances:
Year: 2022 PMID: 35775605 PMCID: PMC9554166 DOI: 10.1177/15353702221106475
Source DB: PubMed Journal: Exp Biol Med (Maywood) ISSN: 1535-3699